Results 101 to 110 of about 20,576 (195)
Cost-effectiveness of age-related macular degeneration study supplements in the UK: combined trial and real-world outcomes data [PDF]
, 2018 Aims To evaluate the cost-effectiveness of Age-Related Eye Disease Study (AREDS) 1 & 2 supplements in patients with either bilateral intermediate age-related macular degeneration, AREDS category 3, or unilateral neovascular age-related macular ...
Agron, E +7 more
core
LifePurpose: To describe the indication spectrum for high-dose 8 mg aflibercept for neovascular age-related macular degeneration (nAMD) in a real-world cohort in a tertiary referral center.
Caspar Liesenhoff +10 more
doaj +1 more source
Cardiotoxicity and cancer therapy [PDF]
, 2014 A fundamental concept of treatment is to do no harm. However, with cancer treatment this is not always possible. Chemotherapy is associated with cardiovascular (CV) complications.1,2 This risk is even greater in the elderly patients and patients with ...
Kolovou, G +2 more
core
Clinical Ophthalmology, 2018 Claudia Taipale,1,2 Ilkka Laine,1,3 Raimo Tuuminen1,3 1Helsinki Retina Research Group, Medicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland; 2Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland; 3Department of
Taipale C, Laine I, Tuuminen R
doaj
American Journal of Ophthalmology Case ReportsPurpose: To compare the safety and efficacy of aflibercept with brolucizumab for recalcitrant diabetic macular edema (DME). Observations: At week 52, no significant visual improvement was noted in the eyes treated with either brolucizumab (P = 0.527) or ...
Debdulal Chakraborty +8 more
doaj +1 more source
Targeted Therapies for Ovarian Cancer [PDF]
, 2016 Epithelial ovarian cancer has the highest mortality rate of all gynaecological malignancies. Most women present with advanced disease and develop a recurrence after radical surgery and chemotherapy.
Grunewald, T, Ledermann, JA
core
Scientific ReportsTo compare the short-term treatment outcomes of aflibercept and faricimab for neovascular age-related macular degeneration (nAMD) during the maintenance treatment period, we included 82 eyes of 74 patients who switched from aflibercept to faricimab ...
Misa Masaoka, Kenji Yamashiro
doaj +1 more source
Ophthalmology and TherapyIntroduction ABP 938 is being developed as a biosimilar candidate to aflibercept reference product (RP), a biologic used for certain angiogenic eye disorders.
Neungseon Seo +14 more
doaj +1 more source
Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes [PDF]
, 2016 core +1 more source
Clinical Ophthalmology, 2019 Naoko Koike,1 Tsuyoshi Otsuji,1 Akiko Tsumura,1 Katsuaki Miki,1 Yukio Sakai,1 Tetsuya Nishimura,1 Kanji Takahashi21Department of Ophthalmology, Kansai Medical University Medical Center, Osaka, Japan; 2Department of Ophthalmology, Kansai Medical ...
Koike N +6 more
doaj